Targeted Therapy Welfare Fund for Breast Cancer – Beacon CSR Programme & Roche Malaysia

Targeted Therapy Welfare Fund for Breast Cancer

Beacon CSR Programme & Roche Malaysia


Breast cancer is the most common cancer in women worldwide. The management of breast cancer is complex in nature and is usually customised specifically for individual patients. 1 in 5 breast cancer patients are tested positive for Human Epidermal growth factor Receptor 2 (HER2). HER2 is a protein in the body that promotes the growth of cancer cells aggressively. For breast cancer patients who are HER2-positive (HER2+), doctors often prescribe a drug called Trastuzumab alongside other treatments such as surgery, chemotherapy and radiotherapy to enhance the outcome of the treatment. This treatment however is very costly and many patients could not afford it. As a result, many such patients risk poor treatment outcome and even recurrences.

The Targeted Therapy Welfare Fund for Breast Cancer is an initiative by Beacon Hospital (CSR) and Roche Malaysia. The objective of this programme is to reduce the financial burden of breast cancer patients by enabling them to gain access to targeted therapy (Trastuzumab). Under this programme, deserving patients are given access to this treatment at a subsidised rate*.

*Terms & conditions apply

Programme Coverage

  • Targeted therapy medicine (Trastuzumab) *subcutaneous
  • Day-care charges/ Drug preparation/ Medical consumables
  • Nursing charges/ Monitoring equipment
Not Included
  • Doctor’s fee (RM150 per cycle only)
  • Lab tests (*if needed)
  • Additional medications (*if needed)
  • Hospitalization / Critical care (*if needed)


  • Malaysian citizen
  • Low income/ Have exhausted finances/ Insufficient insurance coverage*
  • HER2+ Breast cancer patients seeking adjuvant targeted therapy (Trastuzumab) as prescribed by the attending oncologist in Beacon Hospital
  • Non-palliative cases

* Subject to eligibility assessment

Beacon International Specialist Centre Sdn Bhd (621976-D)

No. 1, Jalan 215, Section 51, Off Jalan Templer, 46050 Petaling Jaya, Selangor Malaysia.

☎ Phone: +603 7620 7979 | WhatsApp: +6011 1090 6588

🖷 Fax: +603 7786 0990

✉ Email:

Facebook: Beacon International Specialist Centre


Office Hours: Monday – Friday 8.30am – 6.00pm

Frequently Asked Questions

  1. How do I apply and enrol in this programme?

Patients must first consult our oncologist as outpatient (consultation charges apply). The attending oncologist will then refer the care to Beacon’s CSR office for financial assessment and eligibility. It will take approximately 3 – 5 working days to process the application. We urge applicants to provide supporting documents promptly to avoid delays. Once the application is approved, the patient will be provided with a guarantee letter which will enable the patient to get the treatment done at the agreed subsidized cost.

  1. How much do I need to pay for this treatment

You will need to pay RM2500 per cycle for Trastuzumab treatment*.

  1. I am not from the Klang Valley, how can I enrol in this programme?

You may contact us via phone or email. Alternatively you can get more information from your local support groups. You are still eligible to enrol for this program despite residing outside of the Klang Valley.

  1. Am I still eligible for this programme, if I am a recipient of other CSR welfare funds by Beacon Hospital?

You may be enrolled into more than one CSR Welfare Fund Programmes e.g. (Radiotherapy Welfare Fund, Chemotherapy Welfare Fund, etc) provided you meet the eligibility criteria.

  1. How many cycles of Trastuzumab will I receive under this programme?

Typically, an adjuvant targeted therapy regime for breast cancer patients will compromise of 18 cycles (approximately one year). This is subject to the discretion of the attending oncologist.

  1. What if I am required to take additional medications and/or investigations such as blood tests, booster injections, scans, etc?

Under this programme, the cost of additional medications and/or investigations is to be borne by the patient*.

*Please refer to the programme coverage section